Sonoma Pharmaceuticals
SNOA
18 hedge funds and large institutions have $1.31M invested in Sonoma Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.05% less ownership
Funds ownership: 0.49% → 0.44% (-0.05%)
20% less capital invested
Capital invested by funds: $1.64M → $1.31M (-$328K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.47K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$760 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$85K |
| 2 |
Renaissance Technologies
New York
|
-$22.8K |
| 3 |
Morgan Stanley
New York
|
-$19.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$456 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $666K | -$22.8K | -150 | -3% |
|
|
BA
2
Bard Associates
Chicago,
Illinois
| $336K | – | – | – |
|
|
BCM
3
Bridgeway Capital Management
Houston,
Texas
| $115K | – | – | – |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $83K | +$760 | +5 | +0.9% |
|
5
Acadian Asset Management
Boston,
Massachusetts
| $62K | – | – | – |
|
6
BlackRock
New York
| $25K | – | – | – |
|
|
RE
7
RBC Europe
London,
United Kingdom
| $8.07K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $8K | -$456 | -3 | -5% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $5K | +$5.47K | +36 | New |
|
10
US Bancorp
Minneapolis,
Minnesota
| $4K | – | – | – |
|
|
11
Morgan Stanley
New York
| $1K | -$19.8K | -130 | -94% |
|
12
Osaic Holdings
Scottsdale,
Arizona
| $1K | – | – | – |
|
|
13
HighTower Advisors
Chicago,
Illinois
| – | -$85K | -505 | Closed |
|
SNOA Hedge Fund Activity: Q4 2020 in Review
18 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2020, worth a combined $1.31M — down 20% from $1.64M a quarter earlier.
Fund positioning in SNOA was balanced in Q4 2020: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $5.47K. The largest seller was HighTower Advisors, exiting entirely with an estimated $85K sold.
- 18 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $1.31M of Sonoma Pharmaceuticals stock for Q4 2020, down 20% quarter-over-quarter.
- 1 fund opened new Sonoma Pharmaceuticals positions in Q4 2020 and 1 closed out, a net change of 0 holders.
- The largest Sonoma Pharmaceuticals buyer in Q4 2020 was Tower Research Capital (TRC), an estimated $5.47K added.
- The largest Sonoma Pharmaceuticals seller in Q4 2020 was HighTower Advisors, an estimated $85K sold.
Based on aggregated 13F filings for Q4 2020.